Erenumab in chronic migraine: experience from a UK tertiary centre and comparison with other real-world evidence
No Thumbnail Available
Authors
Khalil, Modar
Moreno‐Ajona, David
Villar‐Martínez, María Dolores
Greenwood, Fiona
Hoffmann, Jan
Goadsby, Peter J.
Check for full-text access
Issue Date
2022
Type
Article
Language
Keywords
Alternative Title
Abstract
BACKGROUND AND PURPOSE: Chronic migraine is a highly disabling primary headache disorder that is the most common diagnosis of patients seen at tertiary headache centres. Typical oral preventive therapies are associated with many limitations that impact their therapeutic utility. Erenumab was the first available calcitonin gene-related peptide monoclonal antibody in the UK. It had proven efficacy in migraine prevention in clinical trials and limited real-world data in tertiary settings. METHODS: We audited our first 92 patients (n = 73 females) with severely disabling chronic migraine who were given monthly erenumab 70 mg sc for 6 months between December 2018 and December 2019. RESULTS: At 3 months, monthly migraine days were significantly reduced by a median of 4 days, and all other variables also showed significant improvement. The improvement was not affected by baseline analgesic use status. More than half of our patients experienced a clinically meaningful improvement in migraine days. No serious adverse events were reported. CONCLUSIONS: Our real-world data with erenumab demonstrate it is effective and well tolerated in managing patients with chronic migraine in a tertiary care setting.
Description
Citation
Publisher
License
Journal
European Journal of Neurology
Volume
29
Issue
8